Document 6598868

November 4, 2014
Company:
ReproCELL, Inc.
Representative: Chikafumi Yokoyama PhD
Contact:
info_en@reprocell.com
Commencement of mutual sales of products from the ReproCELL group companies
This is a notice that our company, as well as our overseas consolidated subsidiaries Reinnervate (UK) and BioServe
(US), has begun selling each other’s products. The products affected by this agreement are as follows:
1. Our company’s main products are functional cells (heart, liver, and nerve cells) used for drug evaluation in the
drug discovery process and as research reagents, specializing in iPS cell research. They are offered to
university and pharmaceutical researchers.
2. Reinnervate’s main products, the Alvetex series, are cultivation plates that through a simple procedure produce
three-dimensional cell cultures that approximate in vivo environments from which more complex cells can be
obtained. They have a wide variety of applications, such as drug development screening and academic research,
for commercial and university researchers conducting cancer and iPS cell research.
3. BioServe’s main products include over 600,000 human biological samples from over 120,000 patients and 700
medical institutions around the world. BioServe offers samples featuring many types of ailments, including
cancer, metabolic disorders, and immune diseases.
Also, Even with Stemgent (US), which handles research reagents for iPS cells, we anticipate that mutual sales will
commence in November. Stemgent has excellent iPS cell technologies such as mRNA reprogramming that is 100
to 1,000 times more efficient compared to traditional methods, and focuses on products used in iPS research, and
offers a wide array of research reagents, including those used in cancer research.
Through acquiring the three group companies of Reinnervate, BioServe, and Stemgent, we can pursue our existing
objective of offering a wider variety of products to our clients in iPS cell research and making further contributions
to the field. Moreover, as the three companies we have acquired offer a family of products targeting cancer
research, we can expand our business operations beyond iPS research to the field of cancer research. In addition
to utilizing the client bases of each of our four companies to the full, we can use sales & marketing methods
tailored to the characteristics of each markets to accelerate our globalization.
(Reference)
Reinnervate：Leading manufacturer in rapidly growing 3D culture market (UK) URL：http://reinnervate.com/
BioServe：One of the largest commercial human tissue banks in the world (US) URL：http://www.bioserve.com/
Stemgent：Full coverage of iPScell technologies (US) URL：https://www.stemgent.com/